Study objective-The aim was to assess the relationship between survival, tumour stage, and the interval from first symptom to diagnosis (SDI, or duration of symptoms).
to diagnosis (SDI, or duration of symptoms).
Design-This was a retrospective follow up study ofa cohort ofpatients registered in the tumour registry of the Hospital del Mar (Barcelona).
Setting-Hospital based tumour registry, with patients derived mainly from the City of Barcelona.
Participants-1247 cases of lung, breast, stomach, colon, or rectal cancer were analysed using survival curves and Cox proportional hazards regression. Subjects (mean age 63-6 years) were followed for a median length of 12-9 months after diagnosis. At the time of diagnosis one fourth of patients had disseminated disease.
Measurements and main results-Based on clinical records, a physician registered the onset time of the first symptom attributable to cancer (from which the SDI is computed), as well as the tumour stage at diagnosis. Other measurements followed standard tumour registry procedures. Overall, the crude mean SDI was 5 15 months (SD 8-03, median 2 03); only 24-5% of cases had an SDI less than a month. Crude mean SDIs by anatomical site were as follows: lung cancer 3 07 months; breast 7-44; stomach 5 34 ; colon 5 74; rectum 5 03. Tumour extension did not appear to be significantly influenced by SDI, only breast cancer showing a distinct pattern of increased extension with increasing SDI. As expected, the probability of survival decreased monotonically with increasing stage in all sites. Tumour site was also a significant predictor of survival, which at one year ranged from 93% for breast cancer to 28% for lung cancer. However, a longer SDI tended sometimes to be associated with a better chance of survival, a fact that was most apparent in colon cancer. All Cox proportional hazards models showed a consistent picture: SDI was not a significant predictor of survival (age and sex adjusted hazard ratios ranging from 097 to 101), neither was sex; age did predict survival, and so did site and stage. 55 we observed slightly longer intervals than those registered based upon clinical notes. Whereas we deem it unlikely that a differential bias favouring any specific subgroup occurred in our study, we cannot rule out the possibility that nondifferential measurement errors (including recall errors) might have obscured a relationship between the duration of symptoms and survival. There is no doubt that more accurate measurements of SDI phases and of tumour stage are needed; with some exceptions,2 56 they are more feasible in specific ad hoc studies than in tumour registry analyses.
One must also seriously consider the possibility that in the low income population here analysed Primary prevention remains the outstanding top priority for cancer control.
